Social media

Innovation is accelerating progress in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions bring together advanced formulation design, real-time dose flexibility, and world-class CMC expertise to si...

ICON is proud to be recognised among the top global companies in the world for female employees. As of 31 December 2024, women make up 70% of our workforce and hold 60% of director-level and above roles—a powerful refle...

With PubsHub Journals & Congresses, you’ll receive real-time alerts for updates, extensions, and changes to deadlines on your personalized watch list. That means fewer surprises - and better decisions. See how easy it is...

Data is the foundation of every decision in clinical development, yet the journey from first patient interaction to final submission is rarely seen in full. Our latest blog takes you behind the scenes to explore how inf...

Central laboratories are under more pressure than ever. Increasingly complex protocols, frequent amendments, and growing data demands require speed, agility, and uncompromising scientific integrity. At ICON Laboratories,...

While multi-pronged global health efforts are essential to combatting HIV, systemic impediments persist. In ICON’s article, learn how drug developers can play a role in reshaping the future of HIV control, and what they ...

Traditional trial settings often fail to reveal the added value of emerging HIV therapies. Explore how developers can plan trials that demonstrate the true advantages and utility of an HIV intervention in the article fro...

What should you consider when choosing a training dataset for your AI-enabled SaMD? Our whitepaper has the answers. Learn about AI models and data best practices and plan for your FDA Pre-Sub. Download it today. https://...

Learn the pros and cons of different AI models for SaMDs. The right model and data training sets are essential to develop your AI-enabled device. Our latest whitepaper lays out the best practices for data and AI models...

Today marked the conclusion of #SCDM Japan in Tokyo, an event dedicated to advancing excellence in clinical data management. Over the past days, industry leaders and professionals came together to explore key topics such...

From exhaustive site visits to intelligent oversight, CRA responsibilities are evolving. ICON’s latest insights in Pharma Times reveal why digital literacy, data interpretation and strategic thinking are now essential sk...

CRAs are at the centre of clinical trial evolution. Risk-based monitoring, intelligent oversight tools and AI are changing how trials are managed. ICON explores what this means for the future in Pharma Times: https://ow....